There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Palatin Technologies (AMEX: PTN), Bluebird Bio (NASDAQ: BLUE) and Immunomedics (NASDAQ: IMMU) with bullish sentiments.
Palatin Technologies (AMEX: PTN)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Palatin Technologies (AMEX: PTN) today and set a price target of $5. The company’s shares closed on Friday at $1.19.
Pantginis noted:
“NDA Buy PDUFA date set for March 23, 2019; project AdCom before year end. This morning, Palatin’s partner, AMAG Pharmaceuticals (AMAG; not rated) announced the acceptance of the NDA for bremelanotide for hypoactive sexual desire disorder (HSDD) in premenopausal women. The FDA has now set a PDUFA date of March 23, 2019. Importantly, this NDA acceptance has triggered a $20 million milestone payment to Palatin (less contracted expenses incurred by AMAG). The key activity for AMAG and Palatin remains prepping for the anticipated AdCom projected in 4Q18.”
According to TipRanks.com, Pantginis has currently no stars on a ranking scale of 0-5 stars, with an average return of -11.0% and a 36.0% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
Palatin Technologies has an analyst consensus of Moderate Buy, with a price target consensus of $5.
See today’s analyst top recommended stocks >>
Bluebird Bio (NASDAQ: BLUE)
In a report released today, John Newman from Canaccord Genuity maintained a Buy rating on Bluebird Bio (NASDAQ: BLUE), with a price target of $250. The company’s shares closed on Friday at $182.40.
According to TipRanks.com, Newman is a 5-star analyst with an average return of 19.0% and a 46.9% success rate. Newman covers the Healthcare sector, focusing on stocks such as Hutchison China MediTech Ltd, Synergy Pharmaceuticals Inc, and Aileron Therapeutics Inc.
Currently, the analyst consensus on Bluebird Bio is Moderate Buy and the average price target is $213.78, representing a 17.2% upside.
In a report issued on May 30, Piper Jaffray also initiated coverage with a Buy rating on the stock with a $240 price target.
Immunomedics (NASDAQ: IMMU)
In a report released today, Phil Nadeau from Cowen & Co. maintained a Buy rating on Immunomedics (NASDAQ: IMMU), with a price target of $30. The company’s shares closed on Friday at $22.71, close to its 52-week high of $23.18.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 15.2% and a 57.2% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Voyager Therapeutics Inc.
Currently, the analyst consensus on Immunomedics is Moderate Buy and the average price target is $30.50, representing a 34.3% upside.
In a report released today, Wells Fargo also reiterated a Buy rating on the stock with a $31 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
